WP
SMMT icon

Woodline Partners’s Summit Therapeutics SMMT Stock Holding History

Woodline Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Hold
214,507
– – 0.01% 786
2026
Q1 		$4.07M Hold
214,507
– – 0.02% 697
2025
Q4 		$3.75M Hold
214,507
– – 0.01% 681
2025
Q3 		$4.43M Buy
214,507
+32,495
+18% +$788K 0.02% 595
2025
Q2 		$3.87M Buy
+182,012
New +$4.15M 0.02% 611

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Woodline Partners's SMMT Position: Q2 2026 in Review

Woodline Partners held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 214,507 shares worth $3.13M. The position accounts for 0.01% of the portfolio, ranked #786.

Woodline Partners first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.43M in Q3 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Woodline Partners held 214,507 shares of Summit Therapeutics worth $3.13M as of Q2 2026.
  • Woodline Partners left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #786 holding.
  • Woodline Partners first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Woodline Partners's Summit Therapeutics position peaked at $4.43M in Q3 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.